Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CASI Files for China Trials of CD19 CAR-T Candidate

publication date: Sep 16, 2019

CASI, a US-China biopharma, reported China has accepted its clinical trial application for its CD19 CAR-T candidate for review. CNCT19 was originally developed by the Institute of Hematology, Chinese Academy of Medical Sciences. CASI acquired global rights to the candidate in June from Juventas Cell Therapy of Tianjin after a CASI subsidiary invested $11.6 million in Juventas. CASI expects CNCT19 will be at least as effective as western CD19 CAR-T therapies, but will cost less because it is manufactured in China by Juventas. More details....

Stock Symbol: (NSDQ: CASI)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.